Follow us on:
Discover 5000+ schemes. Track your portfolio 24X7
MC30 is a curated basket of 30 investment-worthy mutual Fund (MF) schemes.
The new age digital currency to diversify a portfolio.
Visit this section to access live price and charts.
Learn and stay informed about cryptocurrency in India.
Learn, discover & invest in smallcases across different types to build your long term portfolio.
Explore from India`s leading investment managers and advisors curating their strategies as smallcases.
Diversify your portfolio by investing in Global brands.
Pre-configured baskets of stocks & ETFs that you can invest in with a single click. Developed by hedge funds, global asset management companies, experienced wealth management firms and portfolio managers.
Fundamental, Stock Ideas, Multibaggers & Insights
Stock & Index F&O Trading Calls & Market Analysis
Technical Call, Trading Calls & Insights
Commodity Trading Calls & Market Analysis
Currency Derivatives Trading Calls & Insights
Options Trading Advice and Market Analysis
MARKET SMITH INDIA
Model portfolios, Investment Ideas, Guru Screens and Much More
Proprietary system driven Rule Based Trading calls
Curated markets data, exclusive trading recommendations, Independent equity analysis & actionable investment ideas
STOCK REPORTS BY THOMSON REUTERS
Details stock report and investment recommendation
POWER YOUR TRADE
Technical and Commodity Calls
Set price, volume and news alerts
BSE: 531347 | NSE: |
Series: NA |
ISIN: | SECTOR: PharmaceuticalsPharmaceuticals
Bid Price (Qty.)
Offer Price (Qty.)
Gland Pharma’s new product play for FY22 holds a lot of promise
Hold Indoco Remedies; target of Rs 250: ICICI Direct
Buy Natco Pharma; target of Rs 1065: ICICI Direct
Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey
Sanofi India Q4 net declines 58% to Rs 50.5 cr
Merck Dec-qtr net up 25% at Rs 18 cr
Claris Lifesciences net profit up 233 pc at Rs 35 cr in Q3
Sun Pharma Q3 profit dragged by slowdown in US & India sales
Sun Pharma Q3 profit seen up 27%; US & India biz may grow 10%
Aurobindo Q3 profit seen up 14%, revenue may grow 10% on US biz
Lupin Q3 profit seen up 15% to Rs 609cr, US biz may lift revenue
Ranbaxy deal to kick in, Halol overhang on Sun Pharma:Brokerages
Good Q3 but Dr Reddy's still far from sustainable growth: Expert
Sun Pharma Q2 show healthy but margins unsustainable: Nangra
Low earnings for Lupin to continue for next 2 qtrs: IIFL
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.